Adela, Inc
Adela, Inc, based in San Mateo, CA, is pioneering a breakthrough approach to early cancer detection through its innovative technology. By mining the methylome for early indicators of cancer, Adela's genome-wide methylome enrichment platform captures extensive genomic information to enhance test performance and improve treatment decisions.
Utilizing their patented cfMeDIP-seq platform, Adela offers a Research Use Only assay for biopharmaceutical companies in drug discovery and development. Their technology's initial clinical application focuses on Minimal Residual Disease (MRD) testing, providing a tissue-agnostic approach that eliminates the need for tumor samples.
Generated from the website content
Also at this address
You might also like
Partial Data by Infogroup (c) 2025. All rights reserved.